CO2019013887A2 - Composiciones y tratamientos para el trastorno del sueño - Google Patents

Composiciones y tratamientos para el trastorno del sueño

Info

Publication number
CO2019013887A2
CO2019013887A2 CONC2019/0013887A CO2019013887A CO2019013887A2 CO 2019013887 A2 CO2019013887 A2 CO 2019013887A2 CO 2019013887 A CO2019013887 A CO 2019013887A CO 2019013887 A2 CO2019013887 A2 CO 2019013887A2
Authority
CO
Colombia
Prior art keywords
treatments
compositions
sleep disorder
pharmaceutical composition
relates
Prior art date
Application number
CONC2019/0013887A
Other languages
English (en)
Spanish (es)
Inventor
Harry Karelis
Mara Gordon
Stewart Smith
Stewart Washer
Patrizia Washer
Original Assignee
Zelda Therapeutics Operations Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017902338A external-priority patent/AU2017902338A0/en
Application filed by Zelda Therapeutics Operations Pty Ltd filed Critical Zelda Therapeutics Operations Pty Ltd
Publication of CO2019013887A2 publication Critical patent/CO2019013887A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Anesthesiology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
CONC2019/0013887A 2017-06-19 2019-12-10 Composiciones y tratamientos para el trastorno del sueño CO2019013887A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2017902338A AU2017902338A0 (en) 2017-06-19 Sleep Disorder Composition and Treatment Thereof
AU2017904818A AU2017904818A0 (en) 2017-11-29 Sleep Disorder Compositions and Treatments Thereof
PCT/AU2018/050604 WO2018232448A1 (en) 2017-06-19 2018-06-19 COMPOSITION AGAINST SLEEP APNEA AND RELATED TREATMENTS

Publications (1)

Publication Number Publication Date
CO2019013887A2 true CO2019013887A2 (es) 2020-04-01

Family

ID=62947713

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0013887A CO2019013887A2 (es) 2017-06-19 2019-12-10 Composiciones y tratamientos para el trastorno del sueño

Country Status (16)

Country Link
US (2) US20210145910A1 (https=)
EP (1) EP3641754A4 (https=)
JP (1) JP2020524151A (https=)
KR (1) KR20200104278A (https=)
CN (1) CN110944632A (https=)
AU (2) AU2018100837B4 (https=)
BR (1) BR112019026877A2 (https=)
CA (1) CA3065563C (https=)
CL (1) CL2019003635A1 (https=)
CO (1) CO2019013887A2 (https=)
IL (1) IL271503A (https=)
MX (1) MX387442B (https=)
NZ (1) NZ759963A (https=)
PE (1) PE20201163A1 (https=)
SG (1) SG11201912380XA (https=)
WO (1) WO2018232448A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3031810A1 (en) 2016-08-03 2018-02-08 Zelda Therapeutics Operations Pty Ltd Cannabis composition
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
EP3745884A1 (en) 2018-01-31 2020-12-09 Canopy Holdings, Llc Hemp powder
CA3119729A1 (en) 2018-10-10 2020-04-16 Treehouse Biotech, Inc. Synthesis of cannabigerol
CA3027876A1 (en) * 2018-12-18 2020-06-18 Tetra Bio-Pharma Cannabis compositions and methods
NL2022616B1 (en) * 2019-02-21 2020-09-18 Patrick Alexander Unger Cannabigerol and pharmaceutical compositions comprising cannabigerol for use in the treatment of insomnia
US10946054B1 (en) * 2019-10-08 2021-03-16 Jenny's Rose, LLC Therapeutic cannabis extracts
WO2021178579A1 (en) * 2020-03-03 2021-09-10 Alte Verde Llc Cannabis treatment of insomnia, pain, and skin conditions
CA3150874A1 (en) * 2020-03-09 2021-09-16 Anna PERSAUD Compositions comprising functional fragrances and cannabis-derived compounds
CN112057894A (zh) * 2020-09-08 2020-12-11 云南工麻生物科技有限公司 一种提取大麻二酚的方法
CA3200651A1 (en) * 2020-12-04 2022-06-09 Joel Ernest George HARDY Antiinflammatory compositions comprising cannabidiol, delta-9- tetrahydrocannabinol and linalool
CN113143995A (zh) * 2021-01-21 2021-07-23 龙麻(上海)医药研发有限责任公司 一种大麻提取物舌下片及其制备工艺和应用
CN112999218A (zh) * 2021-01-21 2021-06-22 龙麻(上海)医药研发有限责任公司 一种具有镇静助眠功效的组合物及用途
CA3206508A1 (en) * 2021-01-28 2022-08-04 Joseph Palumbo Treatment of sleep apnea with cbd
CN112791151B (zh) * 2021-02-20 2022-04-01 山东新稀宝股份有限公司 一种具有改善睡眠功能的组合物及应用
DK181329B1 (en) 2021-05-04 2023-08-16 Cs Medica As Nasal sleep spray composition, method for its provision, and receptacle and kit comprising said composition
WO2022261662A1 (en) * 2021-06-09 2022-12-15 Demetrix, Inc. Regulation of the sleep/wake cycle using cannabinoid compounds
JP2025503837A (ja) * 2022-01-27 2025-02-06 ディファインド リサーチ，インコーポレイテッド ヒトの回復睡眠を増大させるカンナビジオール（ｃｂｄ）およびテルペンの製剤

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6949582B1 (en) * 1999-05-27 2005-09-27 Wallace Walter H Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment
DE10051427C1 (de) * 2000-10-17 2002-06-13 Adam Mueller Verfahren zur Herstellung eines Tetrahydrocannabinol- und Cannabidiol-haltigen Extraktes aus Cannabis-Pflanzenmaterial sowie Cannabis-Extrakte
DK2311475T3 (en) 2002-08-14 2016-09-19 Gw Pharma Ltd Extraction of pharmaceutically active cannabinoids FROM PLANT MATERIALS
GB2418612A (en) 2004-10-01 2006-04-05 Gw Pharma Ltd Inhibition of tumour cell migration with cannabinoids
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
GB201117956D0 (en) 2011-10-18 2011-11-30 Otsuka Pharma Co Ltd Phytocannabinoids for use in the treatment of breast cancer
AU2013257322A1 (en) 2012-05-03 2014-11-20 Echo Pharmaceuticals B.V. Cannabis plant isolate comprising delta9-tetrahydrocannabinol and a method for preparing such an isolate
US20150313868A1 (en) 2012-12-18 2015-11-05 Kotzker Consulting Llc Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity
US9763991B2 (en) * 2013-06-13 2017-09-19 Cannabis Science International Holding B.V. Composition for the treatment of neurobehavioral disorders
CN103355391A (zh) * 2013-08-13 2013-10-23 汕头大学医学院第一附属医院 一种五味健脑益智饼及其制备方法
US10265292B2 (en) 2013-09-18 2019-04-23 The Werc Shop, LLC Terpene-based compositions, processes methodologies
LT3062606T (lt) 2013-10-29 2019-07-10 Biotech Institute, Llc Specializuotų kanapių selekcija, gamyba, perdirbimas ir panaudojimas
CA2929280A1 (en) 2013-10-31 2015-05-14 Full Spectrum Laboratories, Ltd. Terpene and cannabinoid formulations
CN105010577A (zh) 2014-04-17 2015-11-04 天津市麦地那食品贸易有限公司 一种火麻、橄榄、葡萄籽、葵花籽调和油
US10610512B2 (en) 2014-06-26 2020-04-07 Island Breeze Systems Ca, Llc MDI related products and methods of use
CA2996626A1 (en) 2014-08-25 2016-03-03 Janing Holding Aps Device with compositions for delivery to the lungs, the oral mucosa and the brain
CN107205960A (zh) * 2014-10-21 2017-09-26 联合大麻公司 大麻提取物及其制备和使用方法
MX385464B (es) 2014-12-12 2025-03-18 Ojai Energetics Pbc Composiciones microencapsuladas de cannabinoides
IL253664B (en) * 2015-01-31 2022-09-01 Constance Therapeutics Inc Production method for extracting oil from cannabis and preparations
BR112017018316A2 (pt) 2015-02-27 2018-04-17 Ebbu Llc composições compreendendo combinações de canabinoides purificados, com pelo menos um flavonoide, terpeno ou mineral
CA2986268C (en) * 2015-05-28 2024-01-02 Insys Development Company, Inc. Stable cannabinoid formulations
IL246790A0 (en) * 2016-07-14 2016-09-29 Friedman Doron Self-dissolving compounds of cannabinoids
JP2019526541A (ja) 2016-08-03 2019-09-19 ゼルダ セラピューティクス オペレーションズ ピーティーワイ リミテッド 大麻組成物
CA3031810A1 (en) 2016-08-03 2018-02-08 Zelda Therapeutics Operations Pty Ltd Cannabis composition
US9649349B1 (en) * 2017-01-19 2017-05-16 Metamorphic Alchemy & Distillations, Inc. System and method for producing a terpene-enhanced cannibinoid concentrate
EP3600284A4 (en) * 2017-03-20 2020-12-09 Kanabo Research Ltd. VAPORIZABLE COMPOSITIONS CONTAINING CANNABINOL
US20180352848A1 (en) * 2017-06-07 2018-12-13 NC3 Systems Smokable cannabis-based product with reduced psychoactive effects
SG11202002169TA (en) 2017-09-15 2020-04-29 Zelda Therapeutics Operations Pty Ltd Composition and method for treating autism
EP3745884A1 (en) * 2018-01-31 2020-12-09 Canopy Holdings, Llc Hemp powder
AU2018100924A4 (en) 2018-07-03 2018-08-09 Zelira Therapeutics Operations Pty Ltd Composition and method for treating pain
WO2021248207A1 (en) 2020-06-12 2021-12-16 Zelira Therapeutics Operations Pty Ltd Composition and method for treating chronic pain
PE20240682A1 (es) 2020-11-06 2024-04-10 Zelira Therapeutics Operations Pty Ltd Tecnologia de encapsulacion de cannabinoides

Also Published As

Publication number Publication date
MX387442B (es) 2025-03-18
SG11201912380XA (en) 2020-01-30
AU2018100837A4 (en) 2018-07-26
AU2018100837B4 (en) 2019-02-21
US20210145910A1 (en) 2021-05-20
IL271503A (en) 2020-02-27
WO2018232448A1 (en) 2018-12-27
CA3065563A1 (en) 2018-12-27
PE20201163A1 (es) 2020-10-28
JP2020524151A (ja) 2020-08-13
MX2019015315A (es) 2020-02-17
BR112019026877A2 (pt) 2020-06-30
EP3641754A4 (en) 2021-03-10
CA3065563C (en) 2023-06-13
CL2019003635A1 (es) 2020-06-19
AU2018286647B2 (en) 2024-03-28
US20230270808A1 (en) 2023-08-31
CN110944632A (zh) 2020-03-31
EP3641754A1 (en) 2020-04-29
AU2018286647A1 (en) 2020-01-16
KR20200104278A (ko) 2020-09-03
US12239680B2 (en) 2025-03-04
NZ759963A (en) 2022-07-01

Similar Documents

Publication Publication Date Title
CO2019013887A2 (es) Composiciones y tratamientos para el trastorno del sueño
PE20230607A1 (es) Composicion de cannabis
PE20200726A1 (es) Composicion de cannabis
MX2021008702A (es) Uso de cannabinoides en el tratamiento de las comorbilidades asociadas a la epilepsia.
MX2020005719A (es) Uso de cannabinoides en el tratamiento de epilepsia.
CL2019000268A1 (es) Composición de cannabis.
CL2020003368A1 (es) Composicion y metodo para tratar el dolor
CL2021002646A1 (es) Métodos y composiciones para su uso en el tratamiento del cáncer sin efectos psicosactivos
MX2021006094A (es) Uso de cannabinoides en el tratamiento de epilepsia.
MX2020003934A (es) Uso de cannabidiol en combinacion con agonistas del receptor 5-ht2b o anfetamina en el tratamiento de la epilepsia.
CO2018013654A2 (es) Composiciones nasales de cannabidiol
MX2021006270A (es) Uso de cannabidiol en el tratamiento del complejo de esclerosis tuberosa.
CL2020000632A1 (es) Composición y método para el tratamiento del autismo.
MX2018011348A (es) Composiciones de extractos naturales y uso de los mismos para prevenir o tratar enfermedades.
PE20200338A1 (es) Composiciones cannabinoides novedosas y metodos para tratar la epilepsia infantil
CO2023000130A2 (es) Composición y método para el tratamiento del dolor crónico
CO2021001057A2 (es) Composición y método para el ahorro de opioides
MX2020004232A (es) Composiciones de cannabinoides y sus metodos de uso.
PE20211198A1 (es) Metodos y formulaciones para tratar nauseas y vomitos inducidos por quimioterapia
CO2021001059A2 (es) Composición de cannabinoides y método para tratar el ptsd y/o la ansiedad
MX2018000872A (es) Combinaciones terapeuticas de paclitaxel oralmente administrado y un inhibidor de la bomba de p-glicoproteina (p-gp) para el tratamiento del cancer.
BR112019002213A2 (pt) composições e o uso das mesmas para tratar ou prevenir rosácea
CO2021006279A2 (es) Métodos y tratamientos para la disfunción eréctil
MX2021005573A (es) Uso del compuesto cannabinoide en el tratamiento de la neurodermatitis.
CL2021001076A1 (es) Composición farmacéutica que comprende una combinación de 1,3-2,5% de tetrahidrocannabinol (thc) y 0,6-1,4% de cannabidiol (cbd); su proceso de elaboración; y su uso para el tratamiento del dolor crónico refractario.